Q2 2025 Holdings
Filed 2025-08-14 | 44 holdings | $577.2M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc.(CGEM) | Common | 230031106 | $57.6M | 7,648,268 | 10.0% |
| Madrigal Pharmaceuticals Inc(MDGL) | Common | 558868105 | $30.4M | 100,415 | 5.3% |
| Zai Lab Ltd(ZLAB) | ADR | 98887Q104 | $26.1M | 745,060 | 4.5% |
| Guardant Health Inc(GH) | Common | 40131M109 | $23.0M | 442,656 | 4.0% |
| ARS Pharmaceuticals Inc(SPRY) | Common | 82835W108 | $22.7M | 1,303,399 | 3.9% |
| Edgewise Therapeutics Inc(EWTX) | Common | 28036F105 | $22.6M | 1,720,741 | 3.9% |
| Avidity Biosciences Inc(RNA) | Common | 05370A108 | $21.6M | 760,022 | 3.7% |
| PTC Therapeutics Inc(PTCT) | Common | 69366J200 | $21.4M | 438,477 | 3.7% |
| Trevi Therapeutics Inc(TRVI) | Common | 89532M101 | $18.6M | 3,406,955 | 3.2% |
| Oric Pharmaceuticals Inc(ORIC) | Common | 68622P109 | $17.6M | 1,729,378 | 3.0% |
| Natera Inc(NTRA) | Common | 632307104 | $16.7M | 98,924 | 2.9% |
| Alkermes Plc(ALKS) | Common | G01767105 | $15.7M | 549,262 | 2.7% |
| Moonlake Immunotherapeutics(MLTX) | Class A Ord | 61559X104 | $14.8M | 313,571 | 2.6% |
| MBX Biosciences Inc(MBX) | Common | 55287L101 | $14.8M | 1,294,416 | 2.6% |
| Compass Therapeutics, Inc.(CMPX) | Common | 20454B104 | $14.6M | 5,622,505 | 2.5% |
| Ultragenyx Pharmaceutical Inc(RARE) | Common | 90400D108 | $14.4M | 395,700 | 2.5% |
| Janux Therapeutics Inc(JANX) | Common | 47103J105 | $14.2M | 614,282 | 2.5% |
| Tarsus Pharmaceuticals Inc(TARS) | Common | 87650L103 | $13.8M | 341,496 | 2.4% |
| Dyne Therapeutics, Inc.(DYN) | Common | 26818M108 | $13.8M | 1,446,361 | 2.4% |
| Vera Therapeutics Inc.(VERA) | Class A Ord | 92337R101 | $13.3M | 563,075 | 2.3% |
| Crinetics Pharmaceuticals Inc.(CRNX) | Common | 22663K107 | $12.3M | 428,975 | 2.1% |
| Revolution Medicines, Inc.(RVMD) | Common | 76155X100 | $11.6M | 315,722 | 2.0% |
| Akebia Therapeutics Inc(AKBA) | Common | 00972D105 | $10.5M | 2,889,125 | 1.8% |
| Olema Pharmaceuticals, Inc.(OLMA) | Common | 68062P106 | $10.1M | 2,378,762 | 1.8% |
| Xenon Pharmaceuticals Inc(XENE) | Common | 98420N105 | $10.1M | 323,398 | 1.8% |
| Wave Life Sciences PTE LTD(WVE) | Common | Y95308105 | $9.8M | 1,505,262 | 1.7% |
| DBV Technologies S A(DBVT) | SPONSORED ADS | 23306J309 | $9.6M | 1,054,504 | 1.7% |
| Context Therapeutics Inc(CNTX) | Common | 21077P108 | $9.6M | 14,705,882 | 1.7% |
| Rocket Pharmaceuticals, Inc.(RCKT) | Common | 77313F106 | $9.6M | 3,903,081 | 1.7% |
| Replimune Group Inc(REPL) | Common | 76029N106 | $9.1M | 983,780 | 1.6% |
| Nuvation Bio Inc(NUVB) | Common | 67080N101 | $9.0M | 4,622,590 | 1.6% |
| Stoke Therapeutics Inc(STOK) | Common | 86150R107 | $9.0M | 789,698 | 1.6% |
| Solid Biosciences Inc(SLDB) | Common | 83422E204 | $8.0M | 1,634,569 | 1.4% |
| Relay Therapeutics Inc.(RLAY) | Common | 75943R102 | $7.9M | 2,282,680 | 1.4% |
| Cartesian Therapeutics Inc(RNAC) | Common | 816212302 | $7.1M | 686,007 | 1.2% |
| Taysha Gene Therapies, Inc.(TSHA) | Common | 877619106 | $6.8M | 2,953,562 | 1.2% |
| Sarepta Therapeutics Inc(SRPT) | Common | 803607100 | $5.5M | 321,696 | 1.0% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $4.2M | 50,000 | 0.7% |
| Veru Inc.(VERUEUR) | Common | 92536C103 | $2.9M | 4,911,948 | 0.5% |
| Werewolf Therapeutics, Inc.(HOWL) | Common | 95075A107 | $2.6M | 2,408,810 | 0.5% |
| Design Therapeutics Inc(DSGN) | Common | 25056L103 | $1.9M | 555,187 | 0.3% |
| Repare Therapeutics, Inc.(RPTX) | Common | 760273102 | $1.1M | 819,924 | 0.2% |
| Adaptimmune Therapeutics plc(ADAPY) | Sponsored ADS | 00653A107 | $1.1M | 4,411,821 | 0.2% |
| Arcellx Inc(ACLX) | Common | 03940C100 | $2.4K | 37 | 0.0% |